Medicilon and Soonfast Pharmaceutical signed a collaboration contract on Oct 14. According to the contract, Medicilon will complete the preclinical research of anti-HPV virus and its related disease and apply both the China and USA clinical trials.
Dr. Guodong Li was appointed as VP of CMC by Medicilon. His duty is responsible for the preparation and quality research of the drug.
The 1st Annual Xiamen Bio-Pharmaceutical Companies Salon was held in Xiamen Bio Bay on April 25. The purpose of the salon was to help the executives of bio-pharmaceutical companies in Xiamen to build the platform for idea exchange.
On April 25, HangCang Biological Medicine Association will organized the “1st Bio-Pharmaceutical Enterprises Salon in Xiamen”. The salon aimed for the executives of pharmaceutical companies to build a platform to exchange their ideas. During the summit, Dr. Chunlin Chen, Medicilon CEO, will give a speech with the topic, “The R&D Pattern and Registration for New Drug”.
04/18/2014, Longthera Pharmaceuticals, a pre-clinical stage biopharmaceutical company, based in Jiangsu Province, China, and HQL Pharmaceuticals, a drug discovery company utilizing its super power ChemSpace Scanner (CSS™) computational technology, based in Rehovot, Israel, announced that they have entered into a collaboration agreement for the development of anti cancer small-molecule drug candidate targeting the BCL-2 apoptotic pathway.